Index Ventures Closes $300M Fund for IT, Life Science Companies | GenomeWeb

NEW YORK, July 9 – Index Ventures has closed a new $300 million fund to target information technology and life sciences companies in Europe, the firm said Monday.

A spokeswoman said the firm would target life science businesses developing post-genomic platforms, therapeutics, and nanotechnology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.